Selection of 2 products from
£18.49 to £35.50
Estimated dispatch within 24 working hours.
Estimated dispatch within 2 working days.
Galastop is used to stop the signs of phantom pregnancy in bitches, including the production of milk. Usually the bitch's behaviour signs are the first to respond (such as nesting behaviour) then milk production dries up. Galastop can also be used after the birth of puppies if this is required. Galastop is supplied as a liquid which is given once daily by mouth for at least 4 days. If required, treatment can be continued for up to 12 days. Most bitches respond after a few days.
A pale yellow, viscous non aqueous solution for oral administration containing 50 μg/ml cabergoline in a miglyol base.
Cabergoline is an ergoline derivative with a potent, selective and long-lasting inhibitory effect on prolactin secretion. Prolactin is the key hormone for lactogenesis and for the initiation and maintenance of lactation after parturition. Furthermore the aetiology of false pregnancy is currently thought to be mediated by rising prolactin levels stimulated by falling progesterone levels during the course of metoestrus.
Inhibition of prolactin secretion by cabergoline results in a rapid resolution of the signs of false pregnancy, including lactation and behavioural changes.
Suppression of lactation in the bitch may be required under certain clinical circumstances (for example following removal of puppies soon after birth, or following early weaning). Inhibition of prolactin secretion by Galastop® results in a rapid cessation of lactation and a reduction in the size of the mammary glands.
Galastop® should be administered orally either directly into the mouth or by mixing with food.
The dosage is 0.1 ml/kg bodyweight (equivalent to 5 μg/kg body weight of cabergoline) once daily for 4-6 consecutive days, depending on the severity of the clinical condition.
For dogs less that 5 kg bodyweight it is advisable to measure the dosage in drops, 3 drops being equivalent to 0.1 ml.
If the signs fail to resolve after a single course of treatment, or if they recur after the end of treatment, then the course of treatment may be repeated.
For treatment of false pregnancy, clinical studies have demonstrated efficacy between 80-100%. Behavioural signs are alleviated first, followed by reduction in mammary gland enlargement, then finally suppression of lactation.
Do not use in pregnant animals since Galastop may cause abortion. Do not use in lactating bitches unless suppression of lactation is required.
Galastop may induce transient hypotension in treated animals. Do not use in animals concurrently being treated with hypotensive drugs. Do not use directly after surgery whilst the animal is still under the influence of the anaesthetic agents.
Do not use with dopamine antagonist.
Special warnings for each target species
Additional supportive treatments should involve restriction of water and carbohydrate intake and increase exercise.
Special precautions for use in animals
Cabergoline has the capacity to cause abortion in bitches in the later stages of pregnancy, and under no circumstances should Galastop be used in pregnant bitches.
Cabergoline may induce transient hypotension in treated animals and use of Galastop in animals concurrently being treated with hypotensive drugs, or in animals directly after surgery whilst the animal is still under the influence of anaesthetic agents, might result in more significant hypotension and such usage is contra-indicated.
Use in pregnant animals
Experimental data have shown that cabergoline has the capacity to cause abortion in bitches in the later stages of pregnancy: this effect was seen in all bitches tested. Therefore a contra-indication against use of Galastop in pregnancy is essential.
Induction of hypotension
Experimental data have shown that cabergoline has a hypotensive effect. This side-effect would not be expected to have adverse effects in clinical use because:
- The degree of this effect is not great and would not be expected to have adverse effects in healthy animals;
- In none of the experiments undertaken with cabergoline for whatever purpose and in whatever species has any evidence been observed of any adverse clinical reactions resulting from this hypotensive effect.
Nevertheless if an animal had low blood pressure for other reasons (e.g. concurrent use of hypotensive drugs, influence of anaesthetic agents), cabergoline might have adverse effects, and a warning to prevent usage of Galastop under such conditions is included.
The tolerance data show that cabergoline has emetic activity in the dog. This effect appears to be dose related, and is marked at doses of 10 µg/kg and above (the ED50 – the dose causing emesis in 50% of treated dogs – being calculated at 19 µg/kg).
In the clinical studies vomiting and anorexia was observed is a proportion of bitches treated as recommended for Galastop: in those studies where frequency was recorded, a total of 361 bitches were treated as recommended; of these 28 bitches (8%) vomited and 58 bitches (16%) showed anorexia.
In most cases these adverse effects were transient and of little significance, occurring after the first one or two treatments only. In only 3 bitches in the clinical trials (less that 1%) was treatment stopped because of vomiting.
In a small proportion of cases (qualitative frequency not available), a degree of drowsiness was observed in the first 2 days of treatment.
Interactions between cabergoline and other veterinary medicinal products have not been observed.
Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine receptors, Galastop should not be administered concurrently with drugs which have dopamine antagonist activity (such as phenothiazines, butyrophenones), as these might reduce its prolactin inhibiting effects.
The experimental data indicate that a single overdose with Galastop might result in an increased likelihood of post-treatment vomiting, and possibly an increase in post-treatment hypotension.
General supportive measures should be undertaken to remove any unabsorbed drug and maintain blood pressure, if necessary. It is unlikely that the administration of dopamine antagonist drugs would be necessary, but this course of action could be considered.
Special precautions to be taken by the person administering the medicinal product to animals
Wash hand after use. Avoid contact with skin and eyes wash of any splashes immediately. Care should be taken to avoid contact between the solution and women of childbearing age. Women of childbearing age should wear gloves when administering the product.
For animal treatment only. Keep out of reach and sight of children.
Store below 25°C. Protect from light. Do not refrigerate. After opening, use the product within 28 days. Store in tightly closed original container.
Any unused product or waste materials should be disposed of in accordance with local requirements.
Amber type III glass bottle with screw cap, containing 7 ml or 15 ml 0.005% cabergoline oily solution; supplied with a clear type I glass pipette (graduated dropper) with protective cover.
All prices include VAT where applicable.
Below are some recent questions we've received regarding Galastop Oral Solution for Dogs, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.